Identification
- Generic Name
- Taxifolin
- DrugBank Accession Number
- DB02224
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Taxifolin (DB02224)
- Weight
- Average: 304.2516
Monoisotopic: 304.058302738 - Chemical Formula
- C15H12O7
- Synonyms
- (+)-(2R,3R)-dihydroquercetin
- (+)-dihydroquercetin
- (+)-taxifolin
- (2R,3R)-(+)-taxifolin
- (2R,3R)-3,3',4',5,7-pentahydroxyflavanone
- (2R,3R)-dihydroquercetin
- Dihydroquercetin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Abciximab. Acebutolol Taxifolin may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Taxifolin is combined with Aceclofenac. Acemetacin The risk or severity of adverse effects can be increased when Taxifolin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Acenocoumarol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Benzopyrans
- Chromones
- Flavonoids
- Flavonols
- Heterocyclic Compounds, Fused-Ring
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Pyrans
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as flavanonols. These are compounds containing a flavan-3-one moiety, with a structure characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a hydroxyl group and a ketone at the carbon C2 and C3, respectively.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Flavonoids
- Sub Class
- Flavans
- Direct Parent
- Flavanonols
- Alternative Parents
- 3'-hydroxyflavonoids / 3-hydroxyflavonoids / 4'-hydroxyflavonoids / 5-hydroxyflavonoids / 7-hydroxyflavonoids / Chromones / Catechols / Aryl alkyl ketones / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids show 8 more
- Substituents
- 1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 3'-hydroxyflavonoid / 3-hydroxyflavonoid / 4'-hydroxyflavonoid / 5-hydroxyflavonoid / 7-hydroxyflavonoid / Alcohol / Alkyl aryl ether show 23 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- taxifolin (CHEBI:17948) / Dihyroflavonols (C01617)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9SOB9E3987
- CAS number
- 480-18-2
- InChI Key
- CXQWRCVTCMQVQX-LSDHHAIUSA-N
- InChI
- InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1
- IUPAC Name
- (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-4-one
- SMILES
- O[C@@H]1[C@H](OC2=CC(O)=CC(O)=C2C1=O)C1=CC=C(O)C(O)=C1
References
- General References
- Not Available
- External Links
- PDB Entries
- 1gp5 / 2c29 / 3tvq / 8b7u / 8b7z / 8fen / 8fev
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 0.95 PERRISSOUD,D & TESTA,B (1986) - Predicted Properties
Property Value Source Water Solubility 1.16 mg/mL ALOGPS logP 1.07 ALOGPS logP 1.82 Chemaxon logS -2.4 ALOGPS pKa (Strongest Acidic) 7.74 Chemaxon pKa (Strongest Basic) -4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 127.45 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 74.61 m3·mol-1 Chemaxon Polarizability 29.03 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.965 Blood Brain Barrier - 0.5711 Caco-2 permeable - 0.8957 P-glycoprotein substrate Substrate 0.5629 P-glycoprotein inhibitor I Non-inhibitor 0.9297 P-glycoprotein inhibitor II Non-inhibitor 0.8382 Renal organic cation transporter Non-inhibitor 0.931 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.653 CYP450 1A2 substrate Inhibitor 0.9106 CYP450 2C9 inhibitor Non-inhibitor 0.5823 CYP450 2D6 inhibitor Non-inhibitor 0.9287 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Inhibitor 0.6951 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5822 Ames test Non AMES toxic 0.722 Carcinogenicity Non-carcinogens 0.945 Biodegradation Not ready biodegradable 0.8672 Rat acute toxicity 3.0200 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9781 hERG inhibition (predictor II) Non-inhibitor 0.8161
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 182.8331002 predictedDarkChem Lite v0.1.0 [M-H]- 183.2917002 predictedDarkChem Lite v0.1.0 [M-H]- 168.23116 predictedDeepCCS 1.0 (2019) [M+H]+ 183.9981002 predictedDarkChem Lite v0.1.0 [M+H]+ 185.5557002 predictedDarkChem Lite v0.1.0 [M+H]+ 170.58916 predictedDeepCCS 1.0 (2019) [M+Na]+ 183.1601002 predictedDarkChem Lite v0.1.0 [M+Na]+ 177.32079 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52